Apollo Therapeutics and Sunshine Lake Pharma have signed a license deal for APL-18881, a bi-specific fusion protein targeting ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Privately-held Flare Therapeutics, a US biotech targeting transcription factors to discover precision medicines for oncology ...

New York, USA-based rare neurological disease drug developer Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open ...

Lundbeck’s Q3 2024 revenue rose 18% to $815 million, driven by strategic brands like Vyepti and Rexulti in the USA. Vyepti’s ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

Dutch firm Argenx Euronext: ARGX) and China’s Zai Lab (HKEX: 9688) have received an approval from the National Medical ...

Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa ...

Sino-American oncology company BeiGene (Nasdaq: BGNE) has announced third-quarter 2024 financials, showing the total revenues ...

Intercept Pharmaceuticals, now wholly owned subsidiary of Italy’s Alfasigma, today revealed that the US Food and Drug ...